MTRF1L Inhibitors
Chemical inhibitors of Mitochondrial Translation Release Factor 1-Like (MTRF1L) can interfere with its function in a variety of ways. Cyclosporin A, by binding to the cyclophilins, leads to the inhibition of calcineurin, a phosphatase that normally activates transcription factors crucial for the production of interleukin-2. This inhibition can disrupt cellular pathways that may be necessary for the proper functioning of MTRF1L. Another inhibitor, oligomycin, targets ATP synthase, primarily its F0 subunit, leading to a reduction in cellular ATP levels. Given that numerous cellular processes, including those involving MTRF1L, require ATP, a decrease in this vital molecule can impede MTRF1L activity.
Additional inhibitors act through various mechanisms that affect protein synthesis and processing, where MTRF1L plays a key role. Actinonin, a peptide antibiotic, inhibits aminopeptidases and could disrupt the processing of peptides necessary for MTRF1L's function. Tunicamycin, which inhibits N-linked glycosylation, can cause unfolded protein response and indirectly affect mitochondrial function and protein synthesis. Puromycin causes premature termination by mimicking aminoacyl-tRNA, leading to incomplete protein synthesis and consequently, the inhibition of MTRF1L's role in translation termination. Chloramphenicol binds to the 50S subunit of bacterial ribosomes and can inhibit mitochondrial protein synthesis, directly affecting MTRF1L's function. Emetine and anisomycin both inhibit protein synthesis but at different stages and ribosomal subunits, which could prevent MTRF1L from acting upon its substrates. Ricin and α-amanitin, although acting through distinct pathways involving depurination of rRNA and inhibition of RNA polymerase II respectively, lead to reduced availability of mRNA or damaged ribosomes, thereby indirectly inhibiting MTRF1L. Lastly, diphtheria toxin's ADP-ribosylation of elongation factors can impede protein elongation, affecting the translation process upstream of MTRF1L's action.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that binds to the cyclophilins which inhibits the phosphatase activity of calcineurin. Since calcineurin dephosphorylates NFAT, a transcription factor for interleukin-2, its inhibition prevents NFAT activation. MTRF1L, being a mitochondrial translational release factor, may require a calcium-dependent signaling pathway for proper function. Inhibition of calcineurin could thus impede the pathways necessary for MTRF1L activity. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Oligomycin is an inhibitor of ATP synthase, particularly the F0 subunit. By inhibiting ATP synthase, it reduces ATP levels in the cell, which is essential for numerous cellular processes, including the function of translational release factors like MTRF1L. Lower ATP levels can result in reduced activity of proteins that require ATP for their proper function, potentially including the activities of MTRF1L. | ||||||
Actinonin | 13434-13-4 | sc-201289 sc-201289B | 5 mg 10 mg | $170.00 $385.00 | 3 | |
Actinonin is a peptide antibiotic that acts as an inhibitor of aminopeptidases. Given that MTRF1L is involved in protein synthesis, specifically in termination, the inhibition of peptide processing could disrupt the proper functioning or recycling of MTRF1L, as it may need properly processed peptides to function adequately. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation. While MTRF1L is not glycosylated, the inhibition of glycosylation can lead to ER stress and the unfolded protein response, which can indirectly affect mitochondrial function and protein synthesis, wherein MTRF1L is involved. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during protein synthesis by acting as an analog to aminoacyl-tRNA, thus it can interfere with the translation process in which MTRF1L participates. This results in the release of incomplete peptide chains, which can inhibit the normal function of MTRF1L in mediating the release of complete proteins during the translation termination. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Chloramphenicol binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis. Although MTRF1L is a mitochondrial protein, mitochondria share similarities with bacterial ribosomes, and chloramphenicol can inhibit mitochondrial protein synthesis. This would directly inhibit the function of MTRF1L by preventing the completion of translation in mitochondria. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $440.00 $900.00 $1400.00 $2502.00 | ||
Emetine inhibits protein synthesis by binding to the 40S ribosomal subunit. This binding can block the translocation step of protein synthesis, causing an inhibition of protein elongation. Since MTRF1L is involved in the termination of protein synthesis, the blockage of earlier stages can prevent MTRF1L from acting on its substrates, effectively inhibiting its function. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin inhibits peptidyl transferase activity of the 60S ribosomal subunit. This inhibition impacts peptide bond formation, which is a prerequisite for the release of newly synthesized proteins. MTRF1L, as a release factor, would be unable to perform its role in the absence of completed protein substrates due to the inhibition of peptide bond formation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, which is pivotal for mRNA synthesis. While it does not directly inhibit MTRF1L, the reduction in mRNA available for translation indirectly inhibits MTRF1L's function by reducing the number of proteins that reach the termination phase of protein synthesis where MTRF1L acts. | ||||||